CTChristina G. Towers

Christina G. Towers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christina G. Towers has a total of 87 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The optogenetic tool ASAP acutely inhibits autophagy

    by Payel Mondal, Amanda Cyril, Dana Mamriev, Louis Parham, Igor Wierzbicki, Celina Shen, Ginevra Doglioni, Suzanne Dufresne, Anvita Komarla, David J. Gonzalez, et al.

    Autophagy, a conserved recycling process, manages intracellular quality control to mitigate stress. To determine the rapid effects of autophagy perturbation, we developed an optogenetic tool to rapidly inhibit autophagy, termed ASAP. Our approach leverages light-induced proteolytic cleavage to selectively inhibit autophagy within 5 min of light exposure, providing a precise and dynamic approach to study autophagy regulation. Proteomic profiling with ASAP revealed the most tightly regulated autophagy substrates along with previously unidentified substrates, including nuclear pore complex proteins. Of note, autophagy regulates quality control of cytoplasmic complexes of nucleoporins via specific LC3-interacting regions, sparing nuclear pore complex proteins embedded in the nuclear envelope. Upon rapid autophagy inhibition, incomplete nucleoporin complexes accumulate and instead of undergoing autophagic degradation, cytoplasmic nucleoporin complexes aggregate in processing bodies (P bodies). Using ASAP, we demonstrate rapid and specific inhibition of autophagy, revealing that nuclear pore complex proteins are tightly regulated autophagy substrates.

  • Open Access

    Mitochondrial superoxide–induced mitohormesis is mediated by citrate and cardioprotective

    by Matthew P. Donnelly, Kailash Chandra Mangalhara, Yuening Liu, Kathryn Lande, Gladys R. Rojas, Kym J. Grae, Mack B. Reynolds, Sagnika Ghosh, Neva Olliffe, Pau B. Esparza-Moltó, et al.

    Mitohormesis, whereby transient mitochondrial stress induces adaptive signaling, promotes organismal resilience and longevity in invertebrates, but how this operates in mammals and the underlying metabolic signals involved remain unclear. Using a mouse model of mitohormesis, we show that transient mitochondrial superoxide stress during embryogenesis reprograms the adult heart to enhance mitochondrial biogenesis and antioxidant capacity. These adaptations confer protection against mitochondrial and oxidative injury in models of doxorubicin-induced cardiotoxicity, preserving mitochondrial content and preventing cardiac dysfunction and remodeling. Using a cell model of superoxide-mediated mitohormesis, we find that inhibition of mitochondrial aconitase promotes citrate export to the cytosol, where its conversion to acetyl–coenzyme A drives histone acetylation and mitohormetic protection from oxidative stress. Preventing mitochondrial citrate export abolishes these adaptations, while Aco2 silencing or citrate supplementation recapitulates the response. Together, our findings identify mitochondrial citrate as a redox-sensitive second messenger linking mitochondrial superoxide stress to durable epigenetic and mitohormetic remodeling.

  • Open Access

    Rapid optogenetic blockade of autophagy reveals that nuclear pore complex proteins are robust autophagy substrates

    by Payel Mondal, Amanda Cyril, Dana Mamriev, Louis Parham, Igor Wierzbicki, Celina Shen, David J Gonzalez, Maximiliano A Dangelo, Christina G Towers

    Autophagy, a conserved recycling process, manages intracellular quality control to mitigate stress. To determine the rapid effects of autophagy perturbation, we developed the first optogenetic tool to rapidly inhibit autophagy, termed ASAP. Our approach leverages light-induced proteolytic cleavage to selectively inhibit autophagy within 5 minutes of light exposure, providing a precise and dynamic approach to study autophagy regulation. Proteomic profiling with ASAP revealed the most tightly regulated autophagy substrates along with novel, previously unidentified substrates, including nuclear pore complex (NPC) proteins. Interestingly, autophagy regulates quality control of cytoplasmic complexes of nucleoporins via specific LC3-interacting regions (LIRs), sparing nuclear pore complex proteins embedded in the nuclear envelope. Upon rapid autophagy inhibition, incomplete nucleoporin complexes accumulate and instead of undergoing autophagic degradation, cytoplasmic nucleoporin complexes aggregate in processing bodies (P bodies). Using ASAP, we demonstrate rapid and specific inhibition of autophagy, revealing that nuclear pore complex proteins are tightly regulated autophagy substrates.

  • Open Access

    Leveraging autophagy and pyrimidine metabolism to target pancreatic cancer

    by Suzanne Dufresne, Ramya S Kuna, Kristiana Wong, Anvita Komarla, Angelica Rock, Joel Rosada-Encarnación, Celina Shen, Payel Mondal, Louis R Parham, Fabiana Izidro Layng, et al.

    SUMMARY: Autophagy inhibitors are promising compounds to treat pancreatic ductal adenocarcinoma (PDA) but their efficacy in patients is unclear, highlighting a need to understand mechanisms of resistance. We used a novel approach to uncover metabolic adaptations that bypass autophagy inhibition. Utilizing PDA cells with acquired resistance to different autophagy inhibitors, we found that severe autophagy depletion induces metabolic rewiring to sustain TCA intermediates and nucleotides for biosynthesis. Long-term autophagy inhibition results in altered pyruvate metabolism likely regulated by lower pyrimidine pools. Cells adapting to loss of autophagy preferentially salvage pyrimidines to replenish these pools instead of synthesizing them de novo. Exploiting this metabolic vulnerability, we found that acquired resistance to autophagy inhibition promotes increased salvage and therefore sensitivity to pyrimidine analogues, including gemcitabine and trifluridine/tipiracil leading to combinatory effects with autophagy inhibitors and pyrimidine analogs. These studies provide mechanistic insight defining how autophagy inhibition can be leveraged to treat pancreatic cancer.


  • Black voices in cancer research and oncology

    by Kilan C. Ashad-Bishop, Onyinye D. Balogun, Runcie C. W. Chidebe, Leah M. Cook, Christina Towers

  • Top Cited Papers

    Mitochondrial DNA replication stress triggers a pro-inflammatory endosomal pathway of nucleoid disposal

    by Laura E. Newman, Sammy Weiser Novak, Gladys R. Rojas, Nimesha Tadepalle, Cara R. Schiavon, Danielle A. Grotjahn, Christina G. Towers, Marie-Ève Tremblay, Matthew P. Donnelly, Sagnika Ghosh, et al.

    Mitochondrial DNA (mtDNA) encodes essential subunits of the oxidative phosphorylation system, but is also a major damage-associated molecular pattern (DAMP) that engages innate immune sensors when released into the cytoplasm, outside of cells or into circulation. As a DAMP, mtDNA not only contributes to anti-viral resistance, but also causes pathogenic inflammation in many disease contexts. Cells experiencing mtDNA stress caused by depletion of the mtDNA-packaging protein, transcription factor A, mitochondrial (TFAM) or during herpes simplex virus-1 infection exhibit elongated mitochondria, enlargement of nucleoids (mtDNA–protein complexes) and activation of cGAS–STING innate immune signalling via mtDNA released into the cytoplasm. However, the relationship among aberrant mitochondria and nucleoid dynamics, mtDNA release and cGAS–STING activation remains unclear. Here we show that, under a variety of mtDNA replication stress conditions and during herpes simplex virus-1 infection, enlarged nucleoids that remain bound to TFAM exit mitochondria. Enlarged nucleoids arise from mtDNA experiencing replication stress, which causes nucleoid clustering via a block in mitochondrial fission at a stage when endoplasmic reticulum actin polymerization would normally commence, defining a fission checkpoint that ensures mtDNA has completed replication and is competent for segregation into daughter mitochondria. Chronic engagement of this checkpoint results in enlarged nucleoids trafficking into early and then late endosomes for disposal. Endosomal rupture during transit through this endosomal pathway ultimately causes mtDNA-mediated cGAS–STING activation. Thus, we propose that replication-incompetent nucleoids are selectively eliminated by an adaptive mitochondria–endosomal quality control pathway that is prone to innate immune system activation, which might represent a therapeutic target to prevent mtDNA-mediated inflammation during viral infection and other pathogenic states.


  • Open Access

    Supplemental Table 1 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

    by Lina Y. Dimberg, Christina G. Towers, Kian Behbakht, Taylor J. Hotz, Jihye Kim, Susan Fosmire, Christopher C. Porter, Aik-Choon Tan, Andrew Thorburn, Heide L. Ford

    Supplemental Table 1: Significantly enriched pathways from GIANT analysis

  • Open Access

    Supplemental Legends from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

    by Lina Y. Dimberg, Christina G. Towers, Kian Behbakht, Taylor J. Hotz, Jihye Kim, Susan Fosmire, Christopher C. Porter, Aik-Choon Tan, Andrew Thorburn, Heide L. Ford

  • Open Access

    Supplementary Figures 1-5 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

    by Lina Y. Dimberg, Christina G. Towers, Kian Behbakht, Taylor J. Hotz, Jihye Kim, Susan Fosmire, Christopher C. Porter, Aik-Choon Tan, Andrew Thorburn, Heide L. Ford

    Supplemental Figure 1: TRAIL-resistant BJAB-LexR cells are not resistant to other drugs. Supplemental Figure 2: TRAIL-resistant MDA-MB-231 cells are not resistant to other drugs. Supplemental Figure 3: Knock-down of SLC26A2 does not affect sensitivity tovdoxorubicin and etoposide in TRAIL resistant MDA-MB-231. Supplemental Figure 4: BJAB-LexR cells have increased SLC26A2 and decreased DR4 and DR5. Supplemental Figure 5: SLC26A2 expression correlates with Metastasis prognosis.

  • Open Access

    Supplemental Table 2 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

    by Lina Y. Dimberg, Christina G. Towers, Kian Behbakht, Taylor J. Hotz, Jihye Kim, Susan Fosmire, Christopher C. Porter, Aik-Choon Tan, Andrew Thorburn, Heide L. Ford

    Supplemental Table 2: GSEA analysis for upregualted (enriched) pathways in TRAIL treated BJAB-LEXR vs. BJAB WT